Key result
Estrogen replacement therapy for 12 weeks improved forearm endothelial function in postmenopausal women, with greater improvement in hypertensive versus normotensive patients (49% vs 17%, P<0.05).
Why the study?
Does conjugated equine estrogen improve forearm resistance artery endothelial function in normotensive and hypertensive postmenopausal women?
Does conjugated equine estrogen improve forearm resistance artery endothelial function in normotensive and hypertensive postmenopausal women?
Estrogen replacement therapy improves endothelium-dependent vasodilation in postmenopausal women, with a significantly greater benefit observed in those with hypertension.
Estrogen replacement may improve endothelial function more in hypertensive postmenopausal women; extends observational data but leaves open causal confirmation.
Both menopause and hypertension are associated with endothelial dysfunction and are risk factors for coronary heart disease. We evaluated forearm resistance artery endothelial function in hypertensive postmenopausal women (HPW, n=57) and compared it with endothelial function in normotensive postmenopausal women (NPW, n=67). In addition, we evaluated the effects of long-term estrogen replacement therapy (ERT, conjugated equine estrogen at a dose of 0.625 mg daily for 12 weeks) on endothelial function in HPW (n=10) and NPW (n=35). Forearm blood flow (FBF) was measured by strain-gauge plethysmography during reactive hyperemia to assess endothelium-dependent vasodilation and after sublingual nitroglycerin (NTG) administration to assess endothelium-independent vasodilation. Basal FBF was similar in the NPW and HPW groups. The FBF in the HPW group during reactive hyperemia was significantly lower than that in the NPW group. Increases in FBF after NTG were similar in the 2 groups. ERT decreased the LDL cholesterol concentration and circulating ACE activity and increased estradiol and HDL cholesterol in both groups. Basal blood pressures, heart rate, FBF, and body weight did not change with ERT. After 12 weeks of ERT, the maximal FBF response during reactive hyperemia increased significantly in both groups. The improvement in reactive hyperemia after ERT was significantly greater in the HPW group than in the NPW group (49+/-8 versus 17+/-5%, P<0.05). Changes in FBF after sublingual NTG administration were similar before and after 12 weeks of ERT. These findings suggest that continued ERT improves forearm resistance artery endothelial function in postmenopausal women and that this beneficial effect is greater in patients that are hypertensive.
No takes yet. Share an insight, caveat, or question.
Higashi et al. (2001) studied Hypertension in postmenopausal women (n=124). Estrogen replacement therapy vs. Normotensive postmenopausal women was evaluated on Improvement in reactive hyperemia (maximal forearm blood flow response) (p=<0.05). Estrogen replacement therapy for 12 weeks improved forearm endothelial function in postmenopausal women, with greater improvement in hypertensive versus normotensive patients (49% vs 17%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: